2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. PPAR
  5. PPARγ Isoform
  6. PPARγ Antagonist

PPARγ Antagonist

PPARγ Antagonists (7):

Cat. No. Product Name Effect Purity
  • HY-16578
    GW9662
    		Antagonist 99.87%
    GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
  • HY-13202
    T0070907
    		Antagonist 99.98%
    T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.
  • HY-160162
    SR 11023
    		Antagonist
    SR 11023 is an orally active antagonist of PPARγ, with the IC50 value of 109 nM that plays an important role in diabetic research.
  • HY-114263
    NXT629
    		Antagonist 99.20%
    NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively. NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models.
  • HY-148352
    BAY-4931
    		Antagonist 98.83%
    BAY-4931 is a potent, covalent and selective PPARγ inverse-agonist with an IC50 of 0.17 nM.
  • HY-148351
    BAY-0069
    		Antagonist 98.07%
    BAY-0069 is a potent and selective PPARγ inverse agonist with an IC50 value of 6.3 nM and 24 nM for human PPARγ and mouse PPARγ. BAY-0069 can be used to research cancer.
  • HY-128487
    H-​Trp-​Glu-​OH
    		Antagonist
    H-​Trp-​Glu-​OH is a selective, reversible and cell-permeable PPARγ with a Kd of ~8 µM. H-​Trp-​Glu-​OH might be developed as a possible lead compound in diabetes research.